N-{[2-(propan-2-yloxy)phenyl]methylidene}hydroxylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-{[2-(propan-2-yloxy)phenyl]methylidene}hydroxylamine
• 英文别名: (NE)-N-[(2-propan-2-yloxyphenyl)methylidene]hydroxylamine
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD02257390
• 分子量: 179.22
• InChiKey: SGGONDVWPDMQAJ-YRNVUSSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Inhibitors of serine proteases
  申请人：Cottrell M. Kevin

  公开号：US20070179167A1

  公开（公告）日：2007-08-02

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

  本发明涉及式I的化合物：或其药物可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。
• INHIBITORS OF SERINE PROTEASES
  申请人：Cottrell Kevin M.

  公开号：US20110165120A1

  公开（公告）日：2011-07-07

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

  本发明涉及式I的化合物：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。
• MODULATIONS OF PROTEASE ACTIVATED RECEPTORS
  申请人：Fairlie David Paul

  公开号：US20130184226A1

  公开（公告）日：2013-07-18

  The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
• MODULATORS OF PROTEASE ACTIVATED RECEPTORS
  申请人：Fairlie David

  公开号：US20140315796A1

  公开（公告）日：2014-10-23

  The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities.
• US7985762B2
  申请人：——

  公开号：US7985762B2

  公开（公告）日：2011-07-26